Lucid Diagnostics (LUCD) investor relations material

Executive summary

• Achieved $1.5 million in Q2 2026 revenue with 2,770 EsoGuard tests performed, within the 2,500–3,000 target range.

• Secured first laboratory benefit manager (LBM) commercial coverage policy from Concert, adopted by multiple health plans, expanding commercial adoption.

• Advanced engagement with the Department of Veterans Affairs (VA) and major health systems, focusing on EHR integration and workflow optimization.

• Developed a health economic model showing improved outcomes and cost-effectiveness for EsoGuard.

• Focused on commercializing EsoGuard for early detection of esophageal precancer in GERD patients.

Financial highlights

• Q2 2026 revenue was $1.5 million, up from $1.16 million in Q2 2025; six-month revenue was $2.7 million, up from $2.0 million year-over-year.

• Cash and cash equivalents stood at $33.4 million as of June 30, 2026, flat with year-end.

• Non-GAAP net loss per share improved to $(0.06), while GAAP net loss was $14.7 million ($(0.08)/share) for Q2 2026.

• Non-GAAP operating expenses were $12.3 million, in line with the five-quarter average.

• Cash used in operations for the six months ended June 30, 2026 was $23.4 million.

Outlook and guidance

• Awaiting a positive draft Medicare LCD for EsoGuard, with CMS backlog easing.

• Expect VA contracts to contribute to test volume and revenue in the new budget cycle.

• Maintaining target test volume of 2,500–3,000 per quarter, with plans to scale upon broader reimbursement.

• Anticipate further LBM coverage policies, leveraging Concert as a precedent.

• Continued focus on expanding insurance reimbursement and direct contracting with employers and concierge medicine.